Highly Variable Drug Bioequivalence Could Be Shown Through Scaling – Cmte.
Executive Summary
Bioequivalence for highly variable drugs can be demonstrated using reference scaling in the near term, FDA's Pharmaceutical Science Advisory Committee said
You may also be interested in...
Topical Bioequivalence For Unlike Emulsions Should Be Tested In Vivo – FDA
Bioequivalence of topical dermatologic drugs in different emulsions that target the stratum corneum should be determined through in vivo testing, FDA said
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011